| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Melting point | 122-124°C |
| Density | 1.214 |
| RTECS | ED7771666 |
| Storage temp. | Inert atmosphere,Store in freezer, under -20°C |
| Solubility | Soluble in dimethyl sulfoxide and ethanol. |
| Pka | 9.66±0.43(Predicted) |
| Stability: | Hygroscopic and Moisture Sensitive |
Bortezomib, a modified dipeptidyl boronic acid, is a therapeutic proteasome inhibitors used for the treatment of cancers. It is indicated for the treatment of relapsed multiple myeloma and mantle cell lymphoma. It is capable of inhibiting the mammalian 26S proteasome, which is important in regulating the intracellular concentration of specific proteins to maintain homeostasis within cells. The disruption of 26S proteasome function disrupts normal cellular homeostasis, leading to cytotoxic effect on various kinds of cancer cells.
Bortezomib is the first proteasome inhibitor to be approved b the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. T
Bortezomib, a modified dipeptidyl boronic acid, is a therapeutic proteasome inhibitors used for the treatment of cancers. It is indicated for the treatment of relapsed multiple myeloma and mantle cell lymphoma. It is capable of inhibiting the mammalian 26S proteasome, which is important in regulating the intracellular concentration of specific proteins to maintain homeostasis within cells. The disruption of 26S proteasome function disrupts normal cellular homeostasis, leading to cytotoxic effect on various kinds of cancer cells.
1.Multiple myeloma
This product can be used in combination with melp halan and prednione (MP regimen) for the treatment of multiple myeloma patients who have not previously been treated and are not suitable for high-dose chemotherapy and myelosuppression; Or more than one treatment of relapsed patients with multiple myeloma.
2.Mantle cell lymphoma
This product can be used for the treatment of patients with relapsed or refractory mantle cell lymphoma. This patient received at least one treatment before using this product.
){kind=link}